Publikationen in Zusammenarbeit mit Forschern von University of Bern (51)

2023

  1. Immunization with a Multivalent Listeria monocytogenes Vaccine Leads to a Strong Reduction in Vertical Transmission and Cerebral Parasite Burden in Pregnant and Non-Pregnant Mice Infected with Neospora caninum

    Vaccines, Vol. 11, Núm. 1

  2. In Vitro versus in Mice: Efficacy and Safety of Decoquinate and Quinoline-O-Carbamate Derivatives against Experimental Infection with Neospora caninum Tachyzoites

    Pathogens, Vol. 12, Núm. 3

2022

  1. Common Molecular Targets of a Quinolone Based Bumped Kinase Inhibitor in Neospora caninum and Danio rerio

    International Journal of Molecular Sciences, Vol. 23, Núm. 4

  2. Differential Affinity Chromatography Coupled to Mass Spectrometry: A Suitable Tool to Identify Common Binding Proteins of a Broad-Range Antimicrobial Peptide Derived from Leucinostatin

    Biomedicines, Vol. 10, Núm. 11

  3. Vaccine-Linked Chemotherapy Approach: Additive Effects of Combining the Listeria monocytogenes-Based Vaccine Lm3Dx_NcSAG1 With the Bumped Kinase Inhibitor BKI-1748 Against Neospora caninum Infection in Mice

    Frontiers in Veterinary Science, Vol. 9

2021

  1. A short-term treatment with BKI-1294 does not protect foetuses from sheep experimentally infected with Neospora caninum tachyzoites during pregnancy

    International Journal for Parasitology: Drugs and Drug Resistance, Vol. 17, pp. 176-185

  2. Assessment of the activity of decoquinate and its quinoline‐ o‐carbamate derivatives against toxoplasma gondii in vitro and in pregnant mice infected with t. Gondii oocysts

    Molecules, Vol. 26, Núm. 21

  3. Endochin-like quinolones (ELQs) and bumped kinase inhibitors (BKIs): Synergistic and additive effects of combined treatments against Neospora caninum infection in vitro and in vivo

    International Journal for Parasitology: Drugs and Drug Resistance, Vol. 17, pp. 92-106

  4. In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocysts

    International Journal for Parasitology: Drugs and Drug Resistance, Vol. 16, pp. 90-101

  5. One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases

    Veterinary Parasitology, Vol. 289

2020

  1. Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

    International Journal for Parasitology, Vol. 50, Núm. 5, pp. 413-422

  2. Neospora caninum: Differential proteome of multinucleated complexes induced by the bumped kinase inhibitor BKI-1294

    Microorganisms, Vol. 8, Núm. 6

  3. Neospora caninum: Structure and fate of multinucleated complexes induced by the bumped kinase inhibitor bki-1294

    Pathogens, Vol. 9, Núm. 5

  4. The Impact of BKI-1294 Therapy in Mice Infected With the Apicomplexan Parasite Neospora caninum and Re-infected During Pregnancy

    Frontiers in Veterinary Science, Vol. 7

2019

  1. Development and characterization of monoclonal antibodies against Besnoitia besnoiti tachyzoites

    Parasitology, Vol. 146, Núm. 2, pp. 187-196

  2. Immunization with a cocktail of antigens fused with OprI reduces Neospora caninum vertical transmission and postnatal mortality in mice

    Vaccine, Vol. 37, Núm. 3, pp. 473-483

  3. Toxoplasma gondii infection and toxoplasmosis in farm animals: Risk factors and economic impact

    Food and Waterborne Parasitology, Vol. 15

  4. Treatment with Bumped Kinase Inhibitor 1294 Is Safe and Leads to Significant Protection against Abortion and Vertical Transmission in Sheep Experimentally Infected with Toxoplasma gondii during Pregnancy

    Antimicrobial Agents and Chemotherapy, Vol. 63, Núm. 7

  5. Virulence in Mice of a Toxoplasma gondii Type II Isolate Does Not Correlate With the Outcome of Experimental Infection in Pregnant Sheep

    Frontiers in Cellular and Infection Microbiology, Vol. 9, Núm. JAN

2018

  1. Repurposing of commercially available anti-coccidials identifies diclazuril and decoquinate as potential therapeutic candidates against Besnoitia besnoiti infection

    Veterinary Parasitology, Vol. 261, pp. 77-85